Early Blood Glucose Profile and Neurodevelopmental Outcome at Two Years in Neonatal Hypoxic-ischaemic Encephalopathy
Overview
Affiliations
Background: To examine the blood glucose profile and the relationship between blood glucose levels and neurodevelopmental outcome in term infants with hypoxic-ischaemic encephalopathy.
Methods: Blood glucose values within 72 hours of birth were collected from 52 term infants with hypoxic-ischaemic encephalopathy. Hypoglycaemia [< 46.8 mg/dL (2.6 mmol/L)] and hyperglycaemia [> 150 mg/dL (8.3 mmol/L)] were correlated to neurodevelopmental outcome at 24 months of age.
Results: Four fifths of the 468 blood samples were in the normoglycaemic range (392/468:83.8%). Of the remaining 76 samples, 51.3% were in the hypoglycaemic range and (48.7%) were hyperglycaemic. A quarter of the hypoglycaemic samples (28.2%:11/39) and a third of the hyperglycaemic samples (32.4%:12/37) were recorded within the first 30 minutes of life. Mean (SD) blood glucose values did not differ between infants with normal and abnormal outcomes [4.89(2.28) mmol/L and 5.02(2.35) mmol/L, p value = 0.15] respectively. In term infants with hypoxic-ischaemic encephalopathy, early hypoglycaemia (between 0-6 hours of life) was associated with adverse outcome at 24 months of age [OR = 5.8, CI = 1.04-32)]. On multivariate analysis to adjust for grade of HIE this association was not statistically significant. Late hypoglycaemia (6-72 hours of life) was not associated with abnormal outcome [OR = 0.22, CI (0.04-1.14)]. The occurrence of hyperglycaemia was not associated with adverse outcome.
Conclusion: During the first 72 hours of life, blood glucose profile in infants with hypoxic-ischaemic encephalopathy varies widely despite a management protocol. Early hypoglycaemia (0-6 hours of life) was associated with severe HIE, and thereby; adverse outcome.
Wang C, Jiang H, Wu J, Yu Z, Li Q, Jiang C BMC Pediatr. 2024; 24(1):699.
PMID: 39501186 PMC: 11539697. DOI: 10.1186/s12887-024-05176-1.
Abusaleem M, Ebrahim M, Hamed N, Eladwy M Cureus. 2024; 16(8):e68227.
PMID: 39347282 PMC: 11439448. DOI: 10.7759/cureus.68227.
Vega-Del-Val C, Arnaez J, Ochoa-Sangrador C, Garrido-Barbero M, Garcia-Alix A Front Pediatr. 2024; 12:1363576.
PMID: 38601274 PMC: 11004398. DOI: 10.3389/fped.2024.1363576.
Giordano L, Perri A, Tiberi E, Sbordone A, Patti M, DAndrea V Diagnostics (Basel). 2023; 13(18).
PMID: 37761385 PMC: 10530216. DOI: 10.3390/diagnostics13183018.
Worse Outcomes From HIE Treatment Associated With Extreme Glycemic States.
Chavez-Valdez R, Aziz K, Burton V, Northington F Pediatrics. 2023; 152(4).
PMID: 37655403 PMC: 10522924. DOI: 10.1542/peds.2023-062521.